Achieve Life Sciences is seeking FDA approval for its cytisinicline drug, and HC Wainwright has initiated coverage with a Buy rating.
6 reports, 4 independent
Updated Aug 22
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 6
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Achieve Life Sciences is seeking FDA approval for its cytisinicline drug, and HC Wainwright has initiated coverage with a Buy rating.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Achieve Life Sciences' NDA for cytisinicline received a Complete Response Letter (CRL) from the FDA.Sub-event
Achieve Life Sciences seeks FDA approval for cytisinicline; HC Wainwright issues Buy rating.1 source
The company commercialized its drug cytisinicline for nicotine independence.1 source
- Achieve Life Sciences partnered with Omnicom Group for commercialization of its drug.
Keep exploring
The entities involved
-
Achieve Life Sciences (United States)
organization
Nothing else this week.
- FDA
Related events
- Kroger, based in Cincinnati, is under FDA review due to a cyclospora outbreak.
- The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- The FDA recommended advancement for a new drug application submitted by a company.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- BenzingaAchieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for c
- Simply Wall St.When Will Achieve Life Sciences, Inc. (NASDAQ:ACHV) Turn A Profit? Explore Achieve Life Sciences's Fair Values from the Community and select yours We feel now is a pretty good time to analyse Achieve
- Zacks Small Cap ResearchACHV: Second Quarter Results By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported its second quarter 2025 results and highlighte
- GlobeNewswireAchieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025 SEATTLE and VANCOUVER, B
- Unknown outlet
- Unknown outlet